In a welcome move, NeoGenomics saw its Relative Strength Rating improve from 67 to 71 on Tuesday.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if NeoGenomics can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
NeoGenomics is working on a consolidation with a 21.22 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company posted 0% earnings growth in its most recent report, while sales growth came in at 10%.
The company holds the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
